Versant Venture Capital VI L.P. 13D and 13G filings for LAVA Therapeutics N.V.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-09-23 4:52 pm Sale | 2025-09-19 | 13D | LAVA Therapeutics N.V. LVTX | Versant Venture Capital VI L.P. | 0 0.000% | -2,370,533 (Position Closed) | Filing |
| 2025-09-18 7:08 pm Sale | 2025-09-16 | 13D | LAVA Therapeutics N.V. LVTX | Versant Venture Capital VI L.P. | 2,370,533 9.000% | -1,036,624 (-30.42%) | Filing |
| 2021-04-08 4:31 pm Purchase | 2021-03-29 | 13D | LAVA Therapeutics N.V. LVTX | Versant Venture Capital VI L.P. | 3,407,157 13.400% | 3,407,157 (New Position) | Filing |